Claims
- 1. A method for reducing the range in daily dosages required to control pain in human patients, comprising administering an oral controlled release dosage formulation comprising from about 10 to about 40 mg oxycodone or a salt thereof which provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from a mean of about 10 to about 14 hours after repeated administration every 12 hours through steady-state conditions.
- 2. A method for reducing the range in daily dosages required to control pain in substantially all human patients, comprising administering an oral solid controlled release dosage formulation comprising from about 10 mg to about 160 mg oxycodone or a salt thereof which provides a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from a mean of about 10 to about 14 hours after repeated administration every 12 hours through steady-state conditions.
Parent Case Info
This is a divisional of application Ser. No. 08/081,302, filed Jun. 18, 1993, which is a continuation-in-part of U.S. application Ser. No. 07/800,549, filed Nov. 27, 1991, now U.S. Pat. No. 5,266,331.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4862598 |
Oshlack |
Aug 1989 |
|
4990341 |
Goldie et al. |
Feb 1991 |
|
5266331 |
Oshlack et al. |
Nov 1993 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
81302 |
Jun 1993 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
800549 |
Nov 1991 |
|